Develops therapies for fibromyalgia and chronic fatigue syndrome.
Virios Therapeutics, Inc., headquartered in Alpharetta, Georgia, operates as a pioneering biotechnology company in the developmental stages, specializing in the creation of antiviral therapies tailored to combat diseases linked to abnormal immune responses triggered by viruses. At the forefront of its research is IMC-1, a fixed dose combination comprising famciclovir and celecoxib designed for the treatment of fibromyalgia, showcasing Virios Therapeutics' dedication to addressing complex medical conditions with innovative therapeutic solutions.
In addition to IMC-1, Virios Therapeutics is actively advancing IMC-2, an innovative combination therapy featuring valacyclovir and celecoxib. This therapy is specifically targeted at managing the diverse symptoms associated with long COVID, including fatigue, sleep disturbances, cognitive impairments, pain, autonomic dysfunctions, and anxiety. These developmental initiatives underscore the company's commitment to meeting critical medical needs and improving the quality of life for patients affected by chronic and debilitating conditions.
Originally established as Virios Therapeutics, LLC and rebranded in December 2020, Virios Therapeutics, Inc. was founded in 2012. With a focus on leveraging advanced biotechnological innovations, the company continues to expand its capabilities in antiviral therapies, aiming to redefine treatment standards and make significant advancements in the field of immune-mediated viral diseases.